Ignite Creation Date:
2025-12-25 @ 3:38 AM
Ignite Modification Date:
2026-03-11 @ 3:41 AM
Study NCT ID:
NCT03787602
Status:
UNKNOWN
Last Update Posted:
2023-03-02
First Post:
2018-12-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015266', 'term': 'Carcinoma, Merkel Cell'}], 'ancestors': [{'id': 'D027601', 'term': 'Polyomavirus Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014412', 'term': 'Tumor Virus Infections'}, {'id': 'D018278', 'term': 'Carcinoma, Neuroendocrine'}, {'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000723723', 'term': 'navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid'}, {'id': 'C000609138', 'term': 'avelumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 115}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2019-03-19', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-02', 'completionDateStruct': {'date': '2025-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-02-28', 'studyFirstSubmitDate': '2018-12-06', 'studyFirstSubmitQcDate': '2018-12-21', 'lastUpdatePostDateStruct': {'date': '2023-03-02', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-12-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-11', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cohort 1 Part 1: To determine the KRT-232 RP2D.', 'timeFrame': '10 Weeks', 'description': 'The Safety Review Committee (SRC) will determine RP2D for expansion based on safety and tolerability of each arm.'}, {'measure': 'Cohort 1 Part 2: To determine the objective response rate (ORR) in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy', 'timeFrame': '10 Weeks', 'description': 'ORR will be assessed per RECIST criteria version 1.1 after all subjects have been treated at the RP2D of KRT 232 and completed the second response assessment.'}, {'measure': 'Cohort 2 Part 1: To determine the KRT-232 RP2D in combination with avelumab', 'timeFrame': '28 Days', 'description': 'DLTs will be used to establish the MTD of KRT-232 in combination with avelumab. SRC will determine the RP2D based on the safety of combination of KRT-232 with avelumab.'}, {'measure': 'Cohort 2 Part 2: To determine the objective response rate (ORR) in treatment-naïve subjects with p53WT MCC', 'timeFrame': '10 Weeks', 'description': 'ORR will be assessed per RECIST criteria version 1.1 after all 30 subjects have been treated at the RP2D of in combination with avelumab and have completed the second response assessment.'}, {'measure': 'Cohort 3: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC are chemotherapy naive and have failed anti-PD-1/PD-L.', 'timeFrame': '10 Weeks', 'description': 'ORR will be assessed per RECIST criteria 1.1 by IRC.'}, {'measure': 'Cohort 4: To determine the confirmed overall response rate (ORR) based on IRC assessments in subjects with p53WT MCC who have failed anti-PD-1 or anti-PDL-1 immunotherapy and have had least 1 line of prior chemotherapy.', 'timeFrame': '10 Weeks', 'description': 'ORR will be assessed per RECIST criteria 1.1 by IRC.'}], 'secondaryOutcomes': [{'measure': 'To determine the confirmed ORR based on investigator assessment.', 'timeFrame': '1 year after last subject enrolled.', 'description': 'ORR will be assessed per RECIST criteria 1.1 by investigators.'}, {'measure': 'To determine the duration of response (DoR)', 'timeFrame': '1 year after last subject enrolled', 'description': 'Time from documentation of response (CR or PR as determined by RECIST 1.1) until disease progression.'}, {'measure': 'To determine Progression-free survival (PFS)', 'timeFrame': '1 year after last subject enrolled', 'description': 'Time from initial treatment until disease progression.'}, {'measure': 'To determine overall survival (OS)', 'timeFrame': '1 year after last subject enrolled', 'description': 'Time from initial treatment until death from any cause.'}, {'measure': 'To determine clinical benefit rate (CBR)', 'timeFrame': '1 year after last subject enrolled.', 'description': 'PR, CR or stable disease that last at least 10 weeks, per IRC or investigator assessment.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['navtemadlin (KRT-232)'], 'conditions': ['Merkel Cell Carcinoma']}, 'descriptionModule': {'briefSummary': 'This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* For Cohort 1, 3 and 4 patients must have failed treatment with at least one PD-1 inhibitor or PD-L1 inhibitor for metastatic MCC\n* For Cohort 2, patients must not have received any anti-PD-1 or anti-PD-L1 therapy\n* For Cohort 3, patients must not have received any prior chemotherapy\n* For Cohort 4, patients must have received at least one prior line of chemotherapy\n* ECOG performance status of 0 to 1\n* Histologically confirmed MCC. Disease must be measurable, with at least 1 measurable lesion by RECIST 1.1\n* MCC expressing p53WT based on any CLIA or test approved by local health authority or a validated test (Cohort 1 and 2)\n* MCC expressing p53WT based Central Lab test (Cohort 3 and 4)\n* Adequate hematological, hepatic, and renal functions\n\nExclusion Criteria:\n\n* For Cohort 2, subjects must not have autoimmune disease, medical conditions requiring systemic immunosuppression, prior stem cell transplant, or active infection with HBV or HCV.\n* Patients previously treated with MDM2 antagonist therapies or p53-directed therapies\n* History of major organ transplant\n* Patients with known central nervous system (CNS) metastases that are previously untreated\n* Grade 2 or higher QTc prolongation (\\>480 milli-seconds per NCI-CTCAE criteria, version 5.0)'}, 'identificationModule': {'nctId': 'NCT03787602', 'briefTitle': 'Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Kartos Therapeutics, Inc.'}, 'officialTitle': 'A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients With p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination With Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve', 'orgStudyIdInfo': {'id': 'KRT-232-103'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cohort 1, Arm 1', 'description': 'KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.', 'interventionNames': ['Drug: KRT-232']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1, Arm 1b', 'description': 'KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 23-day cycle.', 'interventionNames': ['Drug: KRT-232']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1, Arm 2b', 'description': 'KRT-232 will be administered orally, once daily (QD) on Days 1-5 in a 28-day cycle.', 'interventionNames': ['Drug: KRT-232']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1, Arm 3', 'description': 'KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 21-day cycle.', 'interventionNames': ['Drug: KRT-232']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1, Arm 5', 'description': 'KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle.', 'interventionNames': ['Drug: KRT-232']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1 Expansion', 'description': 'KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.', 'interventionNames': ['Drug: KRT-232']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 2, Arm 1 KRT-232 in combination with avelumab', 'description': 'KRT-232 will be administered orally, once daily (QD) on Days 1-5, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.', 'interventionNames': ['Drug: KRT-232', 'Drug: Avelumab']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 2, Arm 2 KRT-232 in combination with avelumab', 'description': 'KRT-232 will be administered orally, once daily (QD) on Days 1-7, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.', 'interventionNames': ['Drug: KRT-232', 'Drug: Avelumab']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 2 Expansion', 'description': 'KRT-232 will be administered orally, once daily (QD) per RP2D dose and schedule, in combination with avelumab 800 mg IV on Day 1 and 15 in a 28-day cycle.', 'interventionNames': ['Drug: KRT-232', 'Drug: Avelumab']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 3', 'description': 'KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.', 'interventionNames': ['Drug: KRT-232']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 4', 'description': 'KRT-232 will be administered orally, once daily (QD) per Cohort 1 RP2D dose and schedule.', 'interventionNames': ['Drug: KRT-232']}], 'interventions': [{'name': 'KRT-232', 'type': 'DRUG', 'otherNames': ['navtemadlin'], 'description': 'KRT-232 is an experimental MDM2 anticancer drug taken by mouth.', 'armGroupLabels': ['Cohort 1 Expansion', 'Cohort 1, Arm 1', 'Cohort 1, Arm 1b', 'Cohort 1, Arm 2b', 'Cohort 1, Arm 3', 'Cohort 1, Arm 5', 'Cohort 2 Expansion', 'Cohort 2, Arm 1 KRT-232 in combination with avelumab', 'Cohort 2, Arm 2 KRT-232 in combination with avelumab', 'Cohort 3', 'Cohort 4']}, {'name': 'Avelumab', 'type': 'DRUG', 'otherNames': ['Bavencio'], 'description': 'Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.', 'armGroupLabels': ['Cohort 2 Expansion', 'Cohort 2, Arm 1 KRT-232 in combination with avelumab', 'Cohort 2, Arm 2 KRT-232 in combination with avelumab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Colorado Anschutz Medical Campus', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '33176', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Miami Cancer Institute', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Moffitt', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Northwestern Memorial Hospital', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '40202', 'city': 'Louisville', 'state': 'Kentucky', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Norton Cancer Institute Research', 'role': 'CONTACT'}], 'facility': 'Norton Healthcare', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215-5418', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Dana-Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '10021', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Memorial Sloan-Kettering Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Mount Sinai Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '19111-2434', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'United States', 'facility': 'Fox Chase Cancer Center', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'UPMC Hillman Cancer Center', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Texas MD Anderson', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '22031', 'city': 'Fairfax', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Inova Health Care Services', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}, {'city': 'Woolloongabba', 'status': 'RECRUITING', 'country': 'Australia', 'facility': 'Princess Alexandra Hospital Oncology', 'geoPoint': {'lat': -27.48855, 'lon': 153.03655}}, {'city': 'Blumenau', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Centro Catarinense de Pesquisa (CECAP) - Hospital Santa Catarina de Blumenau', 'geoPoint': {'lat': -26.91944, 'lon': -49.06611}}, {'city': 'Brasília', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Instituto Nacional do Cancer', 'geoPoint': {'lat': -15.77972, 'lon': -47.92972}}, {'city': 'Curitiba', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Centro Intergado de Oncologia', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'city': 'Ijuí', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Centro de Pesquisa Clinica em Oncologia', 'geoPoint': {'lat': -28.38778, 'lon': -53.91472}}, {'city': 'Itajaí', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Clinica De Neoplasias Litoral', 'geoPoint': {'lat': -26.90778, 'lon': -48.66194}}, {'city': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'facility': 'Hospital Paulistano', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'city': 'Toronto', 'status': 'RECRUITING', 'country': 'Canada', 'facility': 'Princess Margaret Cancer Centre', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'city': 'Bordeaux', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU de Bordeaux- Hopital Saint-Andre', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'city': 'Gif-sur-Yvette', 'status': 'RECRUITING', 'country': 'France', 'facility': 'AP-HP Universite Paris Saclay', 'geoPoint': {'lat': 48.68333, 'lon': 2.13333}}, {'city': 'Lille', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU de Lille', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'city': 'Lyon', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU Lyon-Sud', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': 'Cedex 5', 'city': 'Marseille', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Hôpital de la Timone. Aix-Marseille Université', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Montpellier', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU Montpellier', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'city': 'Nantes', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU de Nantes', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'facility': 'Hôpital Saint Louis - APHP', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Tours', 'status': 'RECRUITING', 'country': 'France', 'facility': 'CHU de Tours', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'city': 'Berlin', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Vivantes Network for Health Gmb, Neukölln Clinic', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Cologne', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Uniklinik Koln', 'geoPoint': {'lat': 50.93333, 'lon': 6.95}}, {'city': 'Erlangen', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitätsklinikum Erlangen', 'geoPoint': {'lat': 49.59099, 'lon': 11.00783}}, {'city': 'Essen', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitätsklinikum Essen (AöR)', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'city': 'Heidelberg', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Nationales Centrum für Tumorerkrankungen NCT', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'city': 'Rostock', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitätsklinik Rostock', 'geoPoint': {'lat': 54.0887, 'lon': 12.14049}}, {'city': 'Tübingen', 'status': 'RECRUITING', 'country': 'Germany', 'facility': 'Universitats-Hautklinik Tubingen', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'city': 'Candiolo', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Institute for Cancer Research and Treatment', 'geoPoint': {'lat': 44.95858, 'lon': 7.59812}}, {'city': 'Napoli', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'Istituto Nazionale Tumori IRCCS Fondazione Pascale', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'city': 'Ravenna', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'AUSL della Romagna', 'geoPoint': {'lat': 44.41344, 'lon': 12.20121}}, {'city': 'Siena', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'AOUS Le Scotte', 'geoPoint': {'lat': 43.31822, 'lon': 11.33064}}, {'city': 'Verona', 'status': 'RECRUITING', 'country': 'Italy', 'facility': 'OSP Civile Maggiore Borgo Trento', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}, {'city': 'Groningen', 'status': 'RECRUITING', 'country': 'Netherlands', 'facility': 'University Medical Center Groningen', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'city': 'Goyang-si', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'National Cancer Center', 'geoPoint': {'lat': 37.65639, 'lon': 126.835}}, {'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'status': 'RECRUITING', 'country': 'South Korea', 'facility': 'Severance Hospital Yonsei University Health System', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital Duran i Reynals', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Hospital General Universitario Gregorio Marañn (Madrid)', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Pamplona', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Complejo Hospitalario de Navarra', 'geoPoint': {'lat': 42.81687, 'lon': -1.64323}}, {'city': 'Valencia', 'status': 'RECRUITING', 'country': 'Spain', 'facility': 'Fundacio Investigao Hospital General Universitario de Valencia', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}], 'centralContacts': [{'name': 'John Mei', 'role': 'CONTACT', 'email': 'jmei@kartosthera.com', 'phone': '650-542-0136'}, {'name': 'Emily Houlihan', 'role': 'CONTACT', 'email': 'ehoulihan@kartosthera.com', 'phone': '401-954-8042'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Kartos Therapeutics, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}